Efficacy and safety of once ‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes

ConclusionSwitching from exenatide BID to exenatide QW resulted in reduction in HbA1c, FPG and incidence of hypoglycemia and improvement in beta cell function and treatment satisfaction in patients with T2DM. These findings will be useful for selecting optimal treatment in individuals with T2DM. (Trial registration ID: UMIN000016390 and jRCTs031180320).

Source: Journal of Diabetes Investigation - September 12, 2019 Category: Endocrinology Authors: Yuusuke Watanabe, Yoshifumi Saisho, Jun Inaishi, Kinsei Kou, Akira Yamauchi, Yasuhiko Kanazawa, Yoshiaki Okubo, Mikiya Tokui, Takatoshi Imai, Rie Murakami, Tami Tsuchiya, Hironobu Sasaki, Tatsuhiro Masaoka, Junichiro Irie, Shu Meguro, Hiros Tags: CLINICAL TRIAL Source Type: research